10 Overlooked Penny Stocks to Buy Right Now
This article highlights Prime Medicine, Inc. (NASDAQ: PRME) as an overlooked penny stock with significant upside potential. The company recently received regulatory clearances for its gene-editing therapies, including acceptance of a clinical trial application for PM577a in New Zealand and RMAT designation for PM359 from the FDA. Analysts have upgraded PRME's stock, signaling growing confidence in its innovative genetic medicines.
PRME - Prime Medicine Inc Options
This article provides a detailed financial overview of Prime Medicine Inc (PRME), including its last close price of $3.87, key valuation metrics like market cap and enterprise value, and various financial ratios. It also highlights performance indicators, analyst recommendations, and insider ownership data for the biotechnology company.
Enterprise value to revenue forward of Prime Medicine, Inc. – NASDAQ:PRME
This article provides a brief mention of Prime Medicine, Inc. (NASDAQ:PRME) and its enterprise value to revenue forward metric. The content appears to be a stub or a section within a larger financial data platform, indicating the availability of financial information for the company.
Price to book forward of Prime Medicine, Inc. – NASDAQ:PRME
This article briefly highlights the "Price to book forward" metric for Prime Medicine, Inc., traded under the NASDAQ:PRME symbol. It appears to be a financial data point from a larger platform, likely TradingView, indicating specific financial information for the company. The content itself is very minimal, focusing solely on this single financial metric.
H.C. Wainwright upgrades Prime Medicine stock rating to buy
H.C. Wainwright has upgraded Prime Medicine (NASDAQ:PRME) from Neutral to Buy, setting an $8.00 price target after New Zealand approved the Clinical Trial Application for PM577a, an investigational therapy for Wilson’s Disease. This clearance marks the first clinical authorization for an in vivo Prime Editing therapy from the company, enabling a global Phase 1/2 study to commence in the second half of 2026. Despite the stock being potentially overvalued according to InvestingPro data, and the company burning cash quickly, its strong current ratio offers liquidity, with H.C. Wainwright viewing the clinical clearance as a significant de-risking event.
LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6
LifeSci Capital has reiterated its Buy rating for Prime Medicine (PRME.US) and maintained a target price of $6. The firm's analysis supports a positive outlook for the company.
Prime Medicine Says PM359 Granted US FDA Regenerative Medicine Advanced Therapy Designation
Prime Medicine announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359. PM359 is an investigational Prime Editor designed to correct the genetic cause of chronic granulomatous disease (CGD). The company previously received Orphan Drug Designation from the FDA and the European Medicines Agency (EMA) for PM359 for CGD.
Prime Medicine’s CGD therapy gets FDA RMAT, speeding review
Prime Medicine (PRME) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its investigational therapy PM359, aimed at treating p47phox-deficient chronic granulomatous disease (CGD). This designation, supported by positive Phase 1/2 clinical data, expedites the development and review process, allowing for intensive FDA interaction and eligibility for rolling and priority Biologics License Application review. PM359 now holds multiple fast-track designations, underscoring the urgent need for effective treatments for this serious genetic disorder.
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine, Inc. announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359 for the treatment of p47 phox -deficient chronic granulomatous disease (CGD). This designation is based on promising Phase 1/2 clinical data, including results published in The New England Journal of Medicine, which indicate PM359's potential to address the significant unmet medical needs of CGD patients. The RMAT designation will facilitate expedited development and review, adding to existing Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for PM359.
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine, Inc. announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359 for the treatment of p47 phox-deficient chronic granulomatous disease (CGD). This designation is based on promising Phase 1/2 clinical data, including results published in The New England Journal of Medicine, which showed PM359's potential to provide a one-time, disease-modifying treatment. The RMAT designation will facilitate expedited development and review, adding to existing Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for PM359.
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for its investigational autologous Prime Edited hematopoietic stem cell therapy, PM359, for treating p47 phox -deficient chronic granulomatous disease (CGD). This designation is based on promising Phase 1/2 clinical data, including results published in The New England Journal of Medicine, which showed PM359's potential to provide durable and clinically meaningful restoration of immune cell function. The RMAT status will expedite the therapy's development and review process, adding to its existing Fast Track, Orphan Drug, and Rare Pediatric Disease Designations.
Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Ocular Therapeutix (OCUL)
LifeSci Capital analyst Cory Jubinville maintained a Buy rating on Prime Medicine, Inc. (PRME) with a $6.00 price target. Needham analyst Serge Belanger also maintained a Buy rating on Ocular Therapeutix (OCUL) with an $18.00 price target, aligning with a Strong Buy consensus for the stock. Both companies are viewed favorably by analysts in the Healthcare sector.
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?
Prime Medicine (NASDAQ:PRME) is analyzed for its financial health and growth prospects, particularly focusing on its cash burn rate. The company has a short cash runway of about 10 months, having burnt through US$159m in the last year with US$135m in cash reserves. While revenue increased by 4.9%, its cash burn also rose by 42%, suggesting potential difficulties in raising additional capital without significant shareholder dilution.
Prime Medicine receives clearance for first in vivo gene therapy trial
Prime Medicine Inc. (NASDAQ:PRME) has received clearance from New Zealand's Medicines and Medical Devices Safety Authority for its first in vivo Prime Editing therapy, PM577a, for Wilson Disease. This clearance allows the company to begin a global Phase 1/2 study in the second half of 2026, with initial data expected in 2027. The investigational therapy targets a common mutation in the ATP7B gene responsible for Wilson Disease and is delivered via a single intravenous infusion.
Prime Medicine clears first in vivo gene-editing trial for Wilson disease
Prime Medicine (Nasdaq: PRME) announced that its Clinical Trial Application for PM577a, an investigational in vivo Prime Editing therapy for H1069Q-mutated Wilson Disease, has received clearance from New Zealand Medsafe. This marks the first clinical authorization for Prime Medicine's in vivo Prime Editing, enabling a global open-label Phase 1/2 trial expected to start in the second half of 2026. Initial clinical data from the trial, which aims to precisely correct the root cause of the disease, are anticipated in 2027.
Prime Medicine Announces New Zealand Clearance of Clinical
Prime Medicine, Inc. announced that New Zealand has cleared its Clinical Trial Application (CTA) for PM577a, an investigational Prime Editor for Wilson Disease (WD). This marks the first clinical authorization for an in vivo Prime Editing therapy from the company, enabling the initiation of a global Phase 1/2 study, with initial clinical data expected in 2027. PM577a targets the H1069Q mutation in the ATP7B gene, the most common WD-causing allele in North America and Europe, offering potential for a one-time curative genetic therapy.
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?
Prime Medicine (NASDAQ:PRME) is an unprofitable biotech company with a cash burn of US$159m per year, resulting in a cash runway of only 10 months. While its revenue grew by 4.9%, its cash burn increased by 42% year-on-year, raising concerns about its ability to fund future growth without significant equity dilution. The company's current market capitalization is US$518m, meaning its cash burn equates to about 31% of its market value.
Prime Medicine receives clearance for first in vivo gene therapy trial
Prime Medicine Inc. has received clearance from New Zealand's Medicines and Medical Devices Safety Authority for its first in vivo gene therapy clinical trial for PM577a, an investigational treatment for Wilson Disease. The company plans to initiate a global Phase 1/2 study in the latter half of 2026, with initial results expected in 2027. This milestone highlights Prime Medicine's progress in gene editing, despite rapid cash burn common for clinical-stage biotech firms, and its stock has surged 76% over the past year.
Prime Medicine Inc (PRME) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Prime Medicine Inc (PRME), highlighting its earnings forecast score of 8.00 within the Biotechnology & Medical Research industry. Analysts have set an average price target of $6.00 for PRME, with a majority recommending a "Buy" rating. The report also details expected revenue, EPS for the next quarter, and past performance.
Ocular Therapeutix vs. Prime Medicine: A 2026 Analysis of Medical Innovation Stocks - News and Statistics
This article analyzes two medical innovation companies, Ocular Therapeutix (NASDAQ:OCUL) and Prime Medicine (NASDAQ:PRME), in 2026. Ocular Therapeutix, focusing on ophthalmic drug delivery, reported a revenue decline and significant net loss in fiscal 2025 but has strong liquidity. Prime Medicine, a biotech firm advancing genetic treatments, showed revenue growth in fiscal 2025 despite incurring a large net loss due to heavy R&D investment in its early-stage Prime Editing platform.
Transcript : Prime Medicine, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10
This article is a transcript from Prime Medicine, Inc.'s presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 10:40 AM. The presentation featured Dr. Allan Ryan, CEO of Prime Medicine. The full content of the transcript is reserved for subscribers.
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
This article examines Prime Medicine's financial health, focusing on its cash burn, cash runway, and growth plans. It highlights the company's significant cash reserves as a strength but also points out its negative free cash flow. The analysis suggests that while Prime Medicine has sufficient cash to fund its operations for a period, continued high cash burn could pose future challenges without additional funding or revenue generation.
Prime Medicine (PRME) director receives 75,000 options at $3.06
Jeffrey D. Marrazzo, a director at Prime Medicine, Inc. (PRME), was granted 75,000 stock options on June 5, 2026, with an exercise price of $3.06 per share. These options will vest in full on the earlier of June 5, 2027, or the date of the next annual stockholders' meeting, provided he remains with the company. The options are set to expire on June 5, 2036, and after this grant, Marrazzo holds 75,000 derivative securities of this type.
[Form 4] Prime Medicine, Inc. Insider Trading Activity
Prime Medicine, Inc. director Thomas Cahill was granted 75,000 stock options with an exercise price of $3.06 per share, set to expire on June 5, 2036. The options will vest in full by the earlier of June 5, 2027, or the next annual stockholder meeting, assuming continuous service. This transaction is detailed in a Form 4 SEC filing, which also shows his post-award beneficial ownership of 75,000 derivative shares.
Prime Medicine (PRME) director receives 75,000-share stock option grant
Prime Medicine director Kelly Michael Aaron has been granted a stock option for 75,000 shares of common stock, with an exercise price of $3.06 per share and an expiration date of June 5, 2036. The option vests in full on the earlier of June 5, 2027, or the date of the next annual stockholder meeting, contingent on Aaron's continued service to the company. This grant increases Aaron's direct holdings of stock options to 75,000 underlying shares.
Prime Medicine (PRME) director receives 75,000 stock options at $3.06
Prime Medicine, Inc. director Wendy Chung was granted 75,000 stock options with an exercise price of $3.06 per share. These options are set to vest on the earlier of June 5, 2027, or the company's next annual meeting, contingent on her continued service. The options will expire on June 5, 2036, if not exercised.
Prime Medicine (PRME) awards director 75,000 stock options at $3.06
Prime Medicine, Inc. reported that director Kaye I Foster-Cheek received a grant of 75,000 stock options with an exercise price of $3.06 per share, expiring on June 5, 2036. These options will vest in full by the earlier of June 5, 2027, or the next annual stockholders' meeting, provided continuous service. Following this grant, Foster-Cheek holds 75,000 derivative securities, with no open-market buys or sells reported.
Prime Medicine (PRME) awards director David Schenkein 75,000 stock options
Prime Medicine (PRME) director David P. Schenkein has been granted 75,000 stock options with an exercise price of $3.06 per share, expiring on June 5, 2036. The options will vest in full on the earlier of June 5, 2027, or the date of the next annual stockholders' meeting, provided he remains in continuous service. This transaction is classified as a compensation-related, non-market grant.
PRME News | PRIME MEDICINE INC (NASDAQ:PRME)
This article provides recent news and stock information for PRIME MEDICINE INC (NASDAQ:PRME). It highlights the company's Q1 results, which showed a revenue miss but narrower loss, and upcoming presentations at major healthcare conferences. The stock price closed at $2.82 USD, increasing by 4.06% since the previous close.
Prime Medicine Hopes FDA Will Consider 'Novel' Approval Path for First Candidate
Prime Medicine is in discussions with the FDA regarding a novel approval pathway for its gene-editing candidate, PM359, which treats chronic granulomatous disease (CGD). The company hopes the FDA will consider data from a small number of patients, potentially allowing for accelerated approval, despite initial plans to halt independent CGD development. Prime is addressing challenges associated with developing treatments for extremely rare genetic disorders, including high costs and a limited patient population.
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Prime Medicine, Inc. announced that its CEO, Allan Reine, M.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company, a biotechnology firm focused on gene editing therapies using its proprietary Prime Editing platform, will host a live audio webcast of the presentation on its website. Prime Medicine aims to develop one-time curative genetic therapies for a wide range of diseases.
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Prime Medicine, Inc. announced that its CEO, Allan Reine, M.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company, a biotechnology firm, is focused on developing one-time curative genetic therapies using its proprietary Prime Editing platform. A live audio webcast and replay of the presentation will be available on Prime Medicine's website.
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Prime Medicine, Inc. announced that its CEO, Allan Reine, M.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company, which focuses on developing a new class of genetic therapies using its proprietary Prime Editing platform, aims to repair nearly all types of genetic mutations across various tissues and organs. A live audio webcast and replay of the presentation will be available on the company's website.
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Prime Medicine, Inc. announced that its CEO, Allan Reine, M.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company, a biotechnology firm focused on genetic therapies, will provide a live audio webcast of the presentation on its website. Prime Medicine aims to utilize its proprietary Prime Editing platform to develop curative genetic therapies for various diseases.
Prime Medicine to Present at Jefferies Global Healthcare Conference
Prime Medicine announced that its CEO, Allan Reine, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The company is a biotechnology firm focused on developing gene editing therapies using its proprietary Prime Editing platform. A live audio webcast and replay will be available on Prime Medicine's website.
Prime Medicine to Present at Jefferies Global Healthcare Conference
Prime Medicine, Inc. announced that its CEO, Allan Reine, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The company specializes in delivering one-time curative genetic therapies using its proprietary Prime Editing platform, which aims to precisely repair genetic mutations. Prime Medicine is advancing a diversified portfolio of therapeutic programs targeting liver, lung, and immunology and oncology.
PRME
This page provides a comprehensive overview of Prime Medicine Inc (PRME) stock, including its latest financial data, performance metrics, and analyst ratings. It also lists recent news articles and insider transactions related to the company, highlighting its focus on genetic therapies and strategic updates.
Prime Medicine (PRME) Reports Q1 EPS
Prime Medicine, Inc. (NASDAQ:PRME) reported its Q1 2026 earnings, with an EPS of (28c) against a consensus of (25c), and revenue of $856,000. CEO Allan Reine highlighted the company's progress in advancing Prime Editing technology, with regulatory filings expected for PM577 and PM647, and initial data anticipated in 2027. The company also announced the appointment of Svetlana Makhni as Chief Financial Officer to oversee financial operations.
Prime Medicine (PRME) Reports Q1 EPS
Prime Medicine (PRME) reported its Q1 earnings per share of (28c), missing the consensus estimate of (25c), but revenue of $856,000 exceeded expectations. The company is advancing its Prime Editing technology pipeline, with regulatory applications for PM577 and PM647 expected in the first half and mid-year respectively, and initial data anticipated in 2027. Prime Medicine also recently appointed Svetlana Makhni as Chief Financial Officer to oversee its financial operations.
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Hold Rating
H.C. Wainwright has reiterated its Hold rating on Prime Medicine (PRME.US). This indicates that the firm advises investors to maintain their current positions in the company's stock, suggesting a neutral outlook on its near-term performance.
Prime Medicine (NasdaqGM:PRME) Stock Forecast & Analyst Predictions
Prime Medicine (NasdaqGM:PRME) is forecast to experience declining earnings but significant revenue growth, with analysts predicting a future net loss per share but a higher price target. The company recently appointed new executives and initiated several follow-on equity offerings, while strategically prioritizing its in vivo liver franchise for Wilson's Disease and Alpha-1 Antitrypsin Deficiency. Despite high cash burn and stock volatility, Prime Medicine continues to advance its gene-editing pipeline with promising preclinical data and strategic partnerships.
Prime Medicine, Inc. (PRME) reports Q1 loss, misses revenue estimates
Prime Medicine, Inc. (PRME) reported a Q1 loss, missing revenue estimates. The company's financial performance for the first quarter did not meet analysts' expectations.
Prime Medicine targets 2 liver disease filings in 2026, data due 2027
Prime Medicine reported Q1 2026 financial results, including a net loss of $49.1 million and a cash position of $149.2 million providing runway into 2027. The company is on track to file IND/CTA applications for its Wilson Disease (PM577) and AATD (PM647) programs in 2026, with initial clinical data from both expected in 2027. Additionally, Prime Medicine continues regulatory dialogue for a potential Biologics License Application (BLA) for PM359 in Chronic Granulomatous Disease (CGD).
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine, Inc. reported its first-quarter 2026 financial results, highlighting progress in its Prime Editing platform. The company is on track to file regulatory applications for PM577 in Wilson Disease and PM647 in AATD in mid-2026, with initial clinical data expected in 2027. Additionally, Prime Medicine continues regulatory dialogue for a potential Biologics License Application (BLA) for PM359 in Chronic Granulomatous Disease (CGD) and announced a cash runway into 2027 based on its current financial position.
Prime Medicine (Nasdaq: PRME) Q1 2026 results, cash runway into 2027 and pipeline update
Prime Medicine reported its Q1 2026 financial results, with a narrower net loss of $49.1 million and collaboration revenue of $0.9 million. The company announced a cash runway extending into 2027 and provided updates on its gene-editing pipeline, including planned regulatory filings for PM577 and PM647 in 2026 and continued dialogue for PM359. Additionally, Svetlana Makhni was appointed as Chief Financial Officer.
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine, Inc. announced its Q1 2026 financial results, reporting a net loss of $49.1 million and cash reserves of $149.2 million, providing a runway into 2027. The company is on track to file IND/CTA applications for PM577 (Wilson Disease) in H1 2026 and PM647 (AATD) by mid-2026, with initial clinical data expected in 2027. Prime Medicine also continues regulatory dialogue with the FDA for a BLA filing for PM359 in Chronic Granulomatous Disease (CGD) and recently appointed Svetlana Makhni as CFO.
PRME SEC Filings - Prime Medicine 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Prime Medicine (Ticker: PRME) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It details the types of information found in these regulatory documents, such as financial results, material events, and governance matters. The platform offers AI-powered summaries and analysis to help investors quickly understand key points from the filings.
Prime Medicine (NASDAQ:PRME) Upgraded to Sell at Wall Street Zen
Wall Street Zen has upgraded Prime Medicine (NASDAQ:PRME) from a "strong sell" to a "sell" rating. Despite this, the stock holds a consensus "Moderate Buy" rating among analysts with a target price of $7.38. Prime Medicine, a biotechnology company developing Prime Editing technology, maintains significant institutional ownership and has shown a 52-week trading range of $1.11 to $6.94.
PRME
This page provides a detailed financial overview of Prime Medicine Inc. (PRME), including its stock price, key financial metrics, news headlines, and analyst ratings. The data covers performance indicators, insider transactions, recent announcements, and a history of analyst recommendations, showing a dynamic landscape for the biotechnology company.
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) reported a third-quarter loss of $0.62 per share, which is wider than the Zacks Consensus Estimate of a $0.57 loss per share. The company's revenues for the quarter were $0.65 million, falling short of analyst estimates and representing a significant decline compared to the previous year. This weaker-than-expected financial performance led to a slight dip in the company's stock price after the earnings announcement.
